Midazolam in Pediatric Emergencies: Dosing and Routes of Administration

Midazolam is indispensable in pediatric emergency medicine. Whether for prolonged seizures, anxiolysis before painful procedures, or sedation during emergency care – hardly any other benzodiazepine offers comparable versatility in terms of routes of administration and therapeutic range. Especially in children, where intravenous access is not always immediately available, the non-invasive routes of administration make midazolam the first-line agent of choice. This article systematically reviews the various routes of administration, weight-based dosing, respective onset of action, and the clinically relevant pitfalls you need to know in pediatric emergencies.

Pharmacology Overview

Midazolam belongs to the group of short-acting benzodiazepines and exerts its effect by enhancing GABAergic inhibition in the central nervous system. Compared to diazepam, midazolam has several properties that make it particularly suitable for pediatric emergencies:

• Water solubility at acidic pH: The intravenous solution is water-soluble (pH 3.3) but becomes lipophilic at physiological pH – this enables rapid CNS penetration after absorption.
• Short half-life: The elimination half-life in children ranges from 1.5 to 3.5 hours; in neonates, it is significantly longer (4–12 hours).
• Hepatic metabolism: Via CYP3A4 to the active metabolite α-hydroxymidazolam, which can accumulate particularly in renal insufficiency.
• No venous irritation: Unlike diazepam, midazolam does not cause significant phlebitis.

Effect Profile

The clinically utilized properties include:

• Anticonvulsant
• Anxiolytic
• Sedative
• Amnestic (anterograde amnesia)
• Muscle relaxant

The anticonvulsant potency is particularly relevant: according to current evidence, midazolam is at least equivalent to intravenous diazepam for prolonged seizures in the prehospital setting – and when given via non-intravenous routes, it is even superior – primarily because the time to actual drug administration is shorter.

Indications in Pediatric Emergencies

The most common applications in pediatric emergency medicine are:

• Status epilepticus / prolonged seizure (duration > 5 minutes): Midazolam is first-line therapy here, especially when no IV access is available.
• Procedural sedation: For painful or anxiety-provoking procedures (wound care, fracture reduction, foreign body removal).
• Anxiolysis: Premedication or calming of agitated children.
• Sedation for intubation: As part of Rapid Sequence Induction (RSI), although other hypnotics are often preferred here.

Routes of Administration and Dosing

The choice of route depends on the clinical situation, urgency, and available access. The following overview summarizes the common routes.

Intravenous (IV)

The intravenous route is the gold standard in terms of controllability and reliability of effect.

• Dosing for seizures: 0.1 mg/kg (maximum dose 5 mg), slowly titrated over 1–2 minutes
• Dosing for sedation: 0.05–0.1 mg/kg, titrated to effect
• Onset of action: 1–3 minutes
• Duration of action: 30–60 minutes

Clinical pearls:

• Always titrate slowly – the "bolus-and-wait" strategy prevents oversedation.
• In hemodynamically unstable children, reduce the dose, as circulation time may be prolonged and the risk of significant hypotension exists.
• In obese children, dose based on ideal body weight.

Intranasal (IN)

The intranasal route has established itself as the fastest non-invasive route and is of great importance particularly in the prehospital setting.

• Dosing: 0.2 mg/kg (maximum dose 10 mg, divided between both nostrils)
• Concentration: Ideally use the 5 mg/mL solution to keep the application volume low
• Maximum volume per nostril: 0.3–0.5 mL (with larger volumes, the solution runs into the pharynx and is swallowed instead of absorbed)
• Onset of action: 3–5 minutes
• Bioavailability: approximately 60–90%

Clinical pearls:

• Use a Mucosal Atomization Device (MAD) to achieve fine atomization and thereby better mucosal absorption. Without a MAD, bioavailability is significantly reduced.
• Divide the total volume between both nostrils – this doubles the absorption surface area.
• If the nasopharynx is bloody or congested with mucus, absorption is unreliable. In these cases, switch to an alternative route of administration.
• Intranasal administration causes brief nasal stinging, which the child (or parents) should be prepared for.
• In a seizing child, administration in the lateral position is preferred to minimize aspiration risk in case of concurrent vomiting.

Buccal

Buccal administration is rated by AHA guidelines as equivalent to intranasal administration for prehospital seizure termination. In many European countries, including Austria, pre-filled buccal preparations (Buccolam®) are available.

• Dosing: 0.2 mg/kg (maximum dose 10 mg)
• Pre-filled syringes (Buccolam®): Available in age-adapted doses of 2.5 mg / 5 mg / 7.5 mg / 10 mg
• Onset of action: 5–10 minutes
• Bioavailability: approximately 75%

Administration technique:

1. Apply the solution between the cheek and gum (not sublingual, do not let the child swallow it).
2. In a seizing child: slowly drip the solution into the buccal pouch. Half the dose can be distributed to both sides of the cheeks.
3. Do not place the child supine – prefer the lateral position.

Clinical pearls:

• In a seizing child, there is a risk that the solution may be spat out or aspirated. Nevertheless, evidence shows that buccal administration is superior to rectal diazepam for seizure termination.
• Do not use in children with oral injuries or massive hypersalivation.
• Pre-filled syringes (Buccolam®) are easier for parents and laypeople to use and are therefore frequently prescribed as home emergency medication.

Intramuscular (IM)

Intramuscular administration is a reliable alternative when neither IV access is available nor the nasal/buccal route is suitable.

• Dosing: 0.2 mg/kg (maximum dose 10 mg)
• Onset of action: 5–15 minutes
• Bioavailability: > 90%

Clinical pearls:

• Injection site: vastus lateralis muscle (anterolateral thigh) in infants and toddlers, deltoid muscle from school age onward.
• IM administration is painful and is experienced negatively by the child – but it is a reliable option in emergencies.
• For RSI, the IM route for midazolam cannot be recommended, as the onset of action is too slow and unpredictable.

Rectal

Rectal administration of midazolam is possible but has disadvantages compared to other non-invasive routes.

• Dosing: 0.3–0.5 mg/kg (maximum dose 10 mg)
• Onset of action: 8–15 minutes
• Bioavailability: approximately 40–50% (significantly lower than other routes due to first-pass effect)

Clinical pearls:

• The rectal route is increasingly being replaced by intranasal and buccal administration, as these have faster onset and higher bioavailability.
• Rectal diazepam was long the gold standard for home seizure management and remains an option, but is increasingly being replaced by buccal midazolam.
• In cases of diarrhea or rectal stool, absorption is unreliable.
• Rectal administration can be undignifying for older children – this should be considered when choosing the route.

Intraosseous (IO)

When IV access is not possible and the indication is urgent, midazolam can also be administered via an intraosseous access.

• Dosing: Same as IV (0.1 mg/kg)
• Onset of action: Comparable to IV

Comparative Overview of Routes of Administration

Route	Dose (mg/kg)	Max. Dose	Onset of Action	Bioavailability
IV/IO	0.1	5 mg	1–3 min	100%
Intranasal	0.2	10 mg	3–5 min	60–90%
Buccal	0.2	10 mg	5–10 min	~75%
IM	0.2	10 mg	5–15 min	>90%
Rectal	0.3–0.5	10 mg	8–15 min	40–50%

Pitfalls and Common Errors

Volume Errors with Intranasal Administration

The most common clinical error with intranasal administration is the use of a solution with too low a concentration. If the 1 mg/mL solution is used, a 20 kg child would require an application volume of 4 mL – far too much for the nasal mucosa. The solution runs off, gets swallowed, and the onset of action then corresponds more to oral administration. Always use the 5 mg/mL concentration.

Underestimating Respiratory Depression

Midazolam can cause clinically significant respiratory depression, particularly in combination with opioids or in the presence of pre-existing respiratory compromise. Guidelines require:

• Continuous monitoring (SpO₂, clinical assessment of work of breathing)
• Availability of bag-mask ventilation and suction
• Flumazenil as the specific antagonist within immediate reach (dose: 0.01 mg/kg IV, max. 0.2 mg per single dose)

Dosing Errors in Infants

Neonates and young infants have immature hepatic metabolism and a prolonged half-life. Dosing must be chosen particularly carefully here – often 0.05 mg/kg IV is sufficient. Closer monitoring is mandatory.

Paradoxical Reaction

In approximately 1–5% of children, a paradoxical reaction occurs with agitation, restlessness, and aggression instead of sedation. This phenomenon occurs more frequently in toddlers and children with neurodevelopmental disorders. In an emergency, this must be distinguished from an inadequate anticonvulsant effect.

Repeat Dosing and Escalation

If the initial dose of midazolam does not terminate the seizure within 5 minutes:

1. Administer a second benzodiazepine dose (same dose, same or different route – preferably IV if now available).
2. After two unsuccessful benzodiazepine doses: escalate to a second-line antiepileptic (levetiracetam, phenytoin/fosphenytoin, or valproate IV).
3. Keep track of the total benzodiazepine dose – cumulative respiratory depression increases with each administration.

Special Clinical Scenarios

Febrile Seizure

Although most febrile seizures are self-limiting (< 5 minutes), pharmacological intervention for prolonged febrile seizures is identical to the approach for other seizures. Intranasal or buccal administration is excellently suited for EMS and the emergency department, as these children typically do not have IV access.

Procedural Sedation in the Pediatric Emergency Department

For procedural sedation, midazolam is frequently combined with an analgesic (e.g., ketamine or fentanyl). When midazolam is given alone, pain relief is insufficient – the amnestic effect must not be confused with analgesia. The child may not remember the procedure but will have experienced pain.

• Midazolam intranasal 0.2 mg/kg + fentanyl intranasal 1.5 µg/kg is a commonly used combination.
• With combination administration, the risk of respiratory depression is significantly increased – monitoring and resuscitation readiness are mandatory.

Agitated Child in an Emergency

In cases of extreme agitation (e.g., autism spectrum disorders, intoxications, or psychiatric emergencies), midazolam IM or intranasal can be used for de-escalation. Dosing is as described above. Note that a paradoxical reaction may worsen the situation.

Flumazenil – The Antagonist

Flumazenil specifically reverses the effects of midazolam and is indicated for severe respiratory depression. Important considerations:

• Dose: 0.01 mg/kg IV (max. 0.2 mg per single dose), repeatable up to a max. total dose of 1 mg
• Onset of action: 1–2 minutes
• Duration of action: Shorter than that of midazolam – resedation is possible and requires monitoring
• Contraindication: In children with known epilepsy, flumazenil can lower the seizure threshold and provoke a recurrent seizure

Summary of Key Points

• Midazolam is the benzodiazepine of choice in pediatric emergencies, particularly for seizures.
• Without IV access, intranasal and buccal administration are the preferred routes.
• Always use the 5 mg/mL concentration for intranasal administration and use a MAD.
• Dose based on weight – no "ballpark" standard doses.
• Respiratory depression is the most relevant adverse effect, particularly in combination with opioids, in infants, and with repeated dosing.
• Flumazenil must be available but should only be used with caution in epileptic children.
• After two unsuccessful benzodiazepine doses, consistently escalate to second-line agents.

Practical Training

The safe use of midazolam in pediatric emergencies requires more than theoretical knowledge – correct dose calculation under stress, handling of the MAD atomizer, volume limitations per nostril, and management of complications such as respiratory depression or paradoxical reactions must be practiced regularly in hands-on settings. In the PALS course from Simulation Tirol, you train these scenarios in realistic simulations, calculate weight-based dosing under time pressure, and practice the structured approach to treatment-refractory seizures – from the first benzodiazepine to escalation to second-line agents. The AHA-certified course framework ensures that you are prepared for pediatric emergencies in a guideline-compliant and practice-oriented manner.